Highlights of Contemporary Genetically Altered Models may be contributed or invited and is meant to acquaint toxicologic pathologists with important biological and morphological features of newly established transgenic, knock-out, and related genetically engineered animal models. Although these Highlights will be based upon previously published papers, submissions will be peer reviewed. Suggested format includes background; experimental approach; biological, clinical, and pathologic (lesions, pathogenesis, and histomorphology) features; applications and implications.
lorectal cancer will be responsible for 54,900. Dominant hereditary predispositions appear to be involved in development of colorectal cancer in approximately 15% of cases [reviewed in Kinzler and Vogelstein (12) ]. Of these, familial adenomatous polyposis (FAP) is best defined and accounts for approximately 1 % of all cases of colorectal cancer with an incidence at birth of approximately 1 in 7,000 to 16 ,000 (2) . FAP is an inherited autosomal dominant disease due to a defect in 1 copy of the adenomatous polyposis coli (APC) gene located on chromosome 5q21 (5) . Affected individuals may develop hundreds to thousands of colorectal polyps during the second to third decades of life. Loss of heterozygosity (LOH) through a somatic mutation in the remaining copy of the APC gene occurs as an early critical event in the carcinogenic process and appears necessary for the development of most adenomas and carcinomas [reviewed in Kinzler and Vogelstein (12) ]. Ultimately, an accumulation of mutations is required for carcinogenesis including loss of other tumor suppressor genes (e.g., DCC, p53) and activation of oncogenes (e.g., K-ras) (6) . Traditional treatment of FAP consists of a colectomy in hopes of removing the affected organ before malignancy develops and spreads. Other less frequent but potentially serious problems associated with FAP include increased incidences of multiple oste-oma, desmoid tumors, and tumors of the stomach, small intestines, hepatobiliary system, and thyroid gland (2) .
As with most human diseases, increased understanding of relevant genetic and environmental factors can be greatly enhanced by the availability of appropriate animal models. The first mouse model for FAP, which was developed through a chemically induced germline mutation, was named Min, for multiple intestinal neoplasia (20) . Since that original report in 1990, 2 additional strains of mice have been developed through gene-targeting techniques that have specific mutations in the mouse homolog of the APC gene (7, 24) . Although the current review focuses on the Min mouse and its relevance to human intestinal cancer, each model provides a unique system for studying multiple issues of intestinal tumorigenesis.
EXPERIMENTAL APPROACH
Researchers at McArdle Laboratory for Cancer Research were conducting mutagenesis studies in mice using ethlynitrosourea (ENU) to produce animal strains with single germline mutations (20) . In an experiment in which C57BL/6J (B6) male mice were treated with ENU and bred to AKR/J females, a female offspring exhibiting circling behavior was selected for further study. This mouse was mated to a B6 male to determine whether this trait was heritable. In some of these offspring, a regenerative, adult-onset anemia developed, usually by 60 days of age, that was associated with bloody stools and multiple tumors in the large and small intestines. The circling trait was heritable but was not linked to development of intestinal tumors, and this trait (circling) is no longer carried by these mice. The mutation for intestinal neoplasia, Min, was maintained on the B6 background by crossing heterozygous (Minl+) males with B6 females. Because heterozygous female B6 mice have difficulty maintaining a pregnancy, they have not been used in breedings. The homozygous Min mutation is lethal in utero due to failure of the primitive ectoderm to develop shortly after implantation of the embryo (21) .
BIOLOGIC, CLINICAL, AND

PATHOLOGIC FEATURES
In the original report, intestinal tumors ranged from 1 to 8 mm in diameter and typically were polypoid, pap-illary, or sessile adenomas. Locally invasive carcinomas occurred in older affected mice. Min mice were reported to have a mean life span of 119 ± 31 days and to have an average of 29 -~ 10 tumors in the small and large intestines (20) . Unlike patients with FAP, in which most tumors form in the colon and rectum, those in the Min mouse develop predominantly in the small intestines. Although there are dramatic differences in the number of intestinal lesions in the 2 strains of mice with targeted Apc mutations, multiple intestinal polyps and adenomas (7, 24) and adenocarcinomas (7) of the small intestines remain the predominant findings.
In breeding studies, the Min mutation was inherited by 50% of male and female offspring, which is consistent with a fully penetrant autosomal dominant trait (20) . In the continuing series of studies conducted by researchers at McArdle Laboratory, the Min mutation was linked to the murine homolog of the human APC gene (Apc) (31) .
The Min allele of Apc has a nonsense mutation in codon 850 that is similar to mutations described in some cases of FAP and sporadic colorectal cancer. In studies to map the location of Apc, mice were backcrossed and typed for restriction fragment length polymorphisms and simple sequence length polymorphisms (16) . The gene for Min was located to proximal chromosome 18.
In mice and human beings, another gene that may undergo early mutational changes in intestinal tumorigenesis is the MCC gene (mutated in colorectal cancer), which is located on the same chromosome as APC in human beings (chromosome 5) and Apc in mice (chromosome 18). Also located on chromosome 18 in mice and human beings is the DCC gene (deleted in colorectal cancer)a tumor suppressor gene that is often deleted as a later step in the development of colorectal cancer (6) . Because Apc, Mcc, and Dcc are located on chromosome 18 in the mouse, loss of this chromosome because of somatic mutations is undoubtedly a significant step in intestinal tumorigenesis in the mouse (16) .
Apc is a tumor suppressor gene (5)-a gene for which loss of function is associated with the emergence of cancerous cellular behavior. For Apc and APC to be involved in the formation of colon cancer in Min and FAP, both copies of the gene must be affected, one as a germline and one as a somatic mutation. Somatic mutations in Apc always involve allelic loss (15, 17) , whereas those in APC in human beings are frequently subtle with complete loss of the gene copy being less common (15) . Most of the mutations in APC are inactivating and result in premature termination of transcription with production of a truncated protein (22) . Truncated APC proteins can form heterodimers with normal APC molecules decreasing the function of the wild-type protein, thereby acting through a dominant-negative mechanism (30) . Results from recent experiments, however, indicate that effects of mutations in Apc and APC are expressed primarily through LOH and not through interactions of truncated protein products (15, 17, 24, 25) . As previously noted, mutations in Apc and APC are early, critical events in the development of colorectal cancer. LOH of Apc occurs in 100% of intestinal adenomas in the Min mouse (15, 17) and in approximately 80% of colorectal tumors in patients with FAP and in most tumors in patients with sporadic colorectal cancer [reviewed in Kinzler and Vogelstein (12) and Levy et al (15) ]. Depending on the location of the mutation in Apc or APC, there can be dramatic differences in numbers of intestinal polyps and tumors and in the development of extracolonic abnormalities. For example, in FAP, the location of the mutation in APC appears to influence the development of retinal pigmentation, desmoid tumors, mandibular lesions, and the number of colonic polyps and tumors [reviewed in Kinzler and Vogelstein (12) ]. In mice, similar differences in phenotype occur depending on the location of the mutation in Apc. In heterozygous mice having targeted Apc mutations at codon 716 (Apc°&dquo;6) (23, 24) or 1638 (7) , polyp numbers were significantly greater and fewer, respectively, than those reported for the Min mouse, which has the Apc mutation at codon 850 (20) .
Differences in phenotype also occur between patients with similar mutations in APC (14) or in mice with identical mutations but with different genetic backgrounds. Clearly, modifying factors other than the location of the mutation are indicated. While some of these may be environmental, others may involve the expression of modifier genes (9, 26) . Through studies with the Min mouse, an important modifier of polyp and tumor development has been identified. In crosses of heterozygous males with female mice from strains other than B6 (i.e., AKR and MA), researchers found that, although the mutation remained fully penetrant, the affected offspring lived longer and had significantly fewer intestinal tumors (19) . A modifier locus that was unlinked to Min was being expressed in the AKR and MA strains. Named Mom-1 for modifier of Min-], the locus was mapped to distal chromosome 4 (3) . Approximately 50% of the differences in tumor numbers in the 2 intraspecific backcrosses compared to the B6 was attributed to the genetic variation at Mom-1.
In the mouse, the gene for secretory type II phospholipase A2 (Pla2s) has been strongly implicated as the Mom-1 locus (18) . The B6 mouse carries a mutant allele producing an inactive protein while AKR and MA strains have wild-type alleles and active enzyme. Pla2s catalyzes the hydrolyses of the ester bond in position 2 of glycerophospholipids to produce a free fatty acid (often arachidonic acid) and lysophospholipid. The protective effect of Pla2s in these backcrosses may occur in the intestinal lumen perhaps through modification of dietary fats, a risk factor for intestinal carcinogenesis, through maintenance of normal intestinal flora, or through effects on bactericidal properties of intestinal cell secretions (18) . The gene for Pla2s in human beings has been mapped to chromosome 1 (27) . Although some evidence is consistent with a modifying effect for Pla2s in the development of colorectal cancer in human beings (27) , an association between somatic mutations in Pla2s and colorectal cancer has not been found in several studies (28, 29) . The presence of modifier loci in human beings is an exciting prospect, but detection of such genes awaits difficult human population studies (4).
APPLICATIONS AND IMPLICATIONS
Because of the relevance of the Min mouse, it is being used in a variety of experimental settings to address pertinent biological issues. For example, treatment of Min mice with Bowman-Birk inhibitor, a protease inhibitor from soybeans, produced a 42-50°7o reduction in intestinal tumors (11) . This finding supports the continued use of this compound in clinical trials as a chemopreventive agent for intestinal cancer. In other studies, treatment of Min mice with the nonsteroidal antiinflammatory drugs (NSAIDs) sulindac (1) or piroxicam (10) significantly reduced the development of intestinal tumors. Similar protective effects of NSAIDs occur in patients with FAP (8) . These findings may be related to the inhibitory action of NSAIDs on cyclooxygenase (COX) activities and, therefore, prostaglandin synthesis.
The predisposition for intestinal tumorigenesis in Min and Apc-mutated mice can be used to explore a variety of relevant complex issues. For example, Apc°&dquo;6 mice have been crossed with COX-2-deficient mice to examine the importance of COX-2 in intestinal carcinogenesis (23) . COX-2 is the inducible form of cyclooxygenase and is overexpressed in many intestinal tumors. Numbers of intestinal polyps at 10 wk of age in Apc°'16 heterozygous COX-2 heterozygous knockout mice and in Apc°&dquo;6 heterozygous COX-2 homozygous knockout mice were reduced more than 65 and 85%, respectively, when compared to control mice (Apc°&dquo;6 heterozygous COX-2 wild type). Also, the effect of a selective COX-2 inhibitor (MF tricyclic) on polyp numbers in Apc°&dquo;~ heterozygous mice was examined in this study. At the highest dose level, the compound reduced polyp numbers by 62% compared to controls. Clearly, an impaired ability to produce COX-2, either through a knockout or by selective inhibition, decreased the genetic predisposition for the development of intestinal polyps. This study, which used an Apc-mutated mouse, has established the importance of overexpression of COX-2 in the series of events leading to the development of intestinal cancer. The importance of DNA hypomethylation in intestinal tumorigenesis has been studied in Min mice crossed with mice heterozygous for a mutation in the DNA methyltransferase gene, Dnmt (13) . Compared to Min controls, mice heterozygous for both Min and Dnmt had an average of 59% fewer polyps at 180 days of age. Additionally, mice with the same Min-Dnmt genotype treated with a compound to further decrease the level of DNA methyltransferase had 99.9% fewer polyps than controls.
Dnmt in the Min mouse, in addition to COX-2 and MOM-7, can be added to the growing list of genetic modifiers of Apc.
In a short period of time, the Min mouse has been established as a powerful, relevant model of intestinal carcinogenesis in human beings. Inherent advantages with the Min mouse include a uniform genetic background that avoids the genetic heterogeneity present in human beings and the availability of multiple adenomas with the same Apc mutation (17) . Studies with Min and other Apc-mutated mice have confirmed the significance of mutations in this gene as early critical events in intes-tinal tumorigenesis. The importance of the location of the mutation and of the effects of unlinked modifier genes also have been demonstrated in mice with Apc mutations.
Breedings with other genetically altered mice have helped define the role of other factors in intestinal carcinogenesis. Finally, and perhaps most importantly, the Min mouse is being used in studies examining chemopreventive and therapeutic strategies. Future investigations using mice with Apc mutations will provide invaluable insight into the actions and interactions of this and other factors in the development and treatment of intestinal cancer.
